1. Home
  2. BEAM
  3. BEAM News

Latest Beam Therapeutics Inc. (BEAM) News on December 23, 2024

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEAM

GlobeNewswire

6 days ago

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
BEAM

Insider Monkey

12 days ago

Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
BEAM

Benzinga

14 days ago

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM

Zacks

14 days ago

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
BEAM

BioPharma Dive

14 days ago

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

BEAM

MT Newswires

14 days ago

Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
BEAM

GlobeNewswire

15 days ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
BEAM

GlobeNewswire

16 days ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

BEAM

MT Newswires

17 days ago

Beam Therapeutics Appoints Sravan Emany as CFO

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
BEAM

GlobeNewswire

17 days ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
BEAM

Zacks

18 days ago

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
BEAM

GlobeNewswire

19 days ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
BEAM

GlobeNewswire

a month ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

BEAM

MT Newswires

a month ago

Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink
BEAM

TipRanks

2 months ago

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

BEAM

MT Newswires

2 months ago

Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
BEAM

Zacks

2 months ago

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

BEAM

MT Newswires

2 months ago

RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
BEAM

Simply Wall St.

2 months ago

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

BEAM

MT Newswires

2 months ago

Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ...
BEAM

GuruFocus.com

2 months ago

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ...

BEAM

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Beam Therapeutics Inc Earnings Call

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
BEAM

Benzinga

2 months ago

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

BEAM

MT Newswires

2 months ago

Beam Therapeutics' Q3 Net Loss Narrows, Revenue Falls

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
BEAM

GlobeNewswire

2 months ago

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
BEAM

Zacks

2 months ago

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
BEAM

GlobeNewswire

2 months ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Sickle cell patient dies in Beam study of base editing therapy
BEAM

BioPharma Dive

2 months ago

Sickle cell patient dies in Beam study of base editing therapy

Virgin Wines UK (LON:VINO) Might Be Having Difficulty Using Its Capital Effectively
BEAM

Simply Wall St.

2 months ago

Virgin Wines UK (LON:VINO) Might Be Having Difficulty Using Its Capital Effectively

Three Days Left To Buy Warpaint London PLC (LON:W7L) Before The Ex-Dividend Date
BEAM

Simply Wall St.

2 months ago

Three Days Left To Buy Warpaint London PLC (LON:W7L) Before The Ex-Dividend Date

Conduit Holdings Limited (LON:CRE) is a favorite amongst institutional investors who own 87%
BEAM

Simply Wall St.

2 months ago

Conduit Holdings Limited (LON:CRE) is a favorite amongst institutional investors who own 87%

Is It Time To Consider Buying NIOX Group Plc (LON:NIOX)?
BEAM

Simply Wall St.

2 months ago

Is It Time To Consider Buying NIOX Group Plc (LON:NIOX)?

Be Sure To Check Out Softcat plc (LON:SCT) Before It Goes Ex-Dividend
BEAM

Simply Wall St.

2 months ago

Be Sure To Check Out Softcat plc (LON:SCT) Before It Goes Ex-Dividend

Those who invested in Marshalls (LON:MSLH) a year ago are up 64%
BEAM

Simply Wall St.

2 months ago

Those who invested in Marshalls (LON:MSLH) a year ago are up 64%

Don't Buy Ashmore Group Plc (LON:ASHM) For Its Next Dividend Without Doing These Checks
BEAM

Simply Wall St.

2 months ago

Don't Buy Ashmore Group Plc (LON:ASHM) For Its Next Dividend Without Doing These Checks

Look to Virginia for Early Clues on Election Night Results
BEAM

The Wall Street Journal

2 months ago

Look to Virginia for Early Clues on Election Night Results

Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology
BEAM

Insider Monkey

2 months ago

Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
BEAM

Zacks

2 months ago

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
BEAM

GlobeNewswire

2 months ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow
BEAM

Simply Wall St.

2 months ago

We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow

Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine
BEAM

Insider Monkey

2 months ago

Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine

State Street Corp's Strategic Acquisition in Beam Therapeutics Inc
BEAM

GuruFocus.com

2 months ago

State Street Corp's Strategic Acquisition in Beam Therapeutics Inc

BEAM

MT Newswires

2 months ago

Beam Therapeutics Insider Sold Shares Worth $1,342,752, According to a Recent SEC Filing

BEAM

MT Newswires

2 months ago

Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target

BEAM

MT Newswires

3 months ago

JonesTrading Initiates Beam Therapeutics at Hold

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
BEAM

Zacks

4 months ago

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology
BEAM

Insider Monkey

4 months ago

Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology

Beam Therapeutics Second Quarter 2024 Earnings: Revenues Disappoint
BEAM

Simply Wall St.

4 months ago

Beam Therapeutics Second Quarter 2024 Earnings: Revenues Disappoint

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
BEAM

Zacks

5 months ago

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss

BEAM

MT Newswires

5 months ago

Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
BEAM

Zacks

5 months ago

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
BEAM

GlobeNewswire

5 months ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
BEAM

Zacks

5 months ago

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

Beam Therapeutics Stock Earns RS Rating Jump To 85
BEAM

Investor's Business Daily

5 months ago

Beam Therapeutics Stock Earns RS Rating Jump To 85

CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
BEAM

TipRanks

5 months ago

CRISPR Therapeutics Nears 52-Week Low. Time to Buy?

BEAM

MT Newswires

5 months ago

Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy

BEAM

MT Newswires

5 months ago

HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target

Caribou lays off staff; Roche walks away from Relay
BEAM

BioPharma Dive

5 months ago

Caribou lays off staff; Roche walks away from Relay

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
BEAM

Zacks

5 months ago

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

BEAM

MT Newswires

5 months ago

Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August

Beam Therapeutics Announces Transition of Chief Financial Officer
BEAM

GlobeNewswire

5 months ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now
BEAM

Zacks

5 months ago

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
BEAM

Zacks

5 months ago

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?

BEAM

MT Newswires

5 months ago

RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk

BEAM

MT Newswires

6 months ago

Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
BEAM

Zacks

6 months ago

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
BEAM

GlobeNewswire

6 months ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
BEAM

GlobeNewswire

6 months ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
BEAM

GuruFocus.com

6 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

BEAM

Energy Global

6 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
BEAM

USA TODAY

6 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
BEAM

Business Wire

6 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
BEAM

Business Wire

6 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
BEAM

GlobeNewswire

6 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
BEAM

Reuters

6 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
BEAM

GlobeNewswire

6 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
BEAM

Simply Wall St.

6 months ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
BEAM

AFP

6 months ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
BEAM

Simply Wall St.

6 months ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
BEAM

Simply Wall St.

6 months ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
BEAM

Barrons.com

6 months ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
BEAM

Simply Wall St.

6 months ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
BEAM

Simply Wall St.

6 months ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?
BEAM

Simply Wall St.

6 months ago

Should You Buy OVB Holding AG (ETR:O4B) For Its Upcoming Dividend?

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
BEAM

Zacks

7 months ago

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
BEAM

GlobeNewswire

7 months ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
BEAM

GlobeNewswire

7 months ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

15 Best ARK Stocks To Buy Now
BEAM

Insider Monkey

7 months ago

15 Best ARK Stocks To Buy Now

Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
BEAM

Simply Wall St.

7 months ago

Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
BEAM

Zacks

7 months ago

Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
BEAM

GlobeNewswire

7 months ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

BEAM

GuruFocus.com

8 months ago

Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview

BEAM

MT Newswires

8 months ago

Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
BEAM

GlobeNewswire

8 months ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
BEAM

Zacks

8 months ago

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
BEAM

Zacks

8 months ago

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
BEAM

Simply Wall St.

8 months ago

Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
BEAM

Zacks

9 months ago

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
BEAM

GlobeNewswire

9 months ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BEAM

Simply Wall St.

10 months ago

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Share on Social Networks: